Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Mar 26, 2023 in Lung cancer | 0 comments

In a nutshell

This study evaluated the effectiveness and safety outcomes of atezolizumab (Tecentriq) given before surgery for the treatment of patients with non-small cell lung cancer (NSCLC). The data showed that atezolizumab given before surgery was safe and effective for patients with NSCLC.

Some background

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. NSCLC is responsible for around 85% of all lung cancer diagnoses. Standard treatment for advanced NSCLC involves surgical removal of solid tumors, chemotherapy, and radiotherapy.

Immunotherapy has been found to be effective in advanced NSCLC. PD-L1 is a protein that can be found in high numbers on cancer cells. It shuts down the immune system so that cancer cells can grow and spread without detection. Atezolizumab is an immunotherapy that targets PD-L1. Blocking PD-L1 restores the capacity of the immune system to attack and kill cancer cells. Most patients have been treated with atezolizumab after surgery. However, the effectiveness and safety of first-line treatment with atezolizumab given before surgery in patients with NSCLC are still unknown.

Methods & findings

This study involved 143 patients with stage IB-IIIB NSCLC. All patients received atezolizumab alone before surgery. The main outcome was a major pathological response (MPR). MPR was defined as a  volume of 10% or less of tumor cells remaining. The average follow-up time was 3 years.

The percentage of patients who achieved MPR was 20%. The complete response (CR; complete disappearance of cancer cells) was 6%.

After 3 years, the overall survival rate was 80%. The most common side effects were fatigue (39%) and pain (29%).

The bottom line

This study concluded that atezolizumab alone given before surgery was safe and effective for patients with NSCLC.

The fine print

This study was funded by Genentech, the manufacturer of atezolizumab. There was no control group. Larger studies are needed.

Published By :

Nature Medicine

Date :

Sep 12, 2022

Original Title :

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.

click here to get personalized updates